How are energy investors positioned?
Aclarion, Inc. (NASDAQ:ACON), a medical laboratory services provider, has entered into a material definitive agreement with an institutional investor on Monday, according to a statement filed with the Securities and Exchange Commission (SEC). The Broomfield, Colorado-based company has agreed to issue and sell 400,000 shares of its common stock at a price of $0.29 per share, resulting in gross proceeds of $116,000.
This transaction is part of an at-the-market offering under Nasdaq rules and was conducted pursuant to Aclarion’s Form 1-A, which was initially filed with the SEC on June 11, 2024, and qualified on June 24, 2024. The sale was made without the assistance of a placement agent, and no fees or commissions will be paid in connection with the transaction.
Aclarion has also indicated that it has the option to raise additional funds of up to approximately $29.68 million under the same terms and conditions through the qualified Offering Statement. However, as of now, the company has not entered into any additional agreements for such sales and cannot guarantee future transactions.
The deal comes as Aclarion, which was formerly known as Nocimed, Inc. and underwent a name change on February 26, 2015, continues to navigate the market as an emerging growth company. The additional capital raised may be used to fund the company's operations, invest in technology, or for other corporate purposes.
In other recent news, healthcare technology company Aclarion, Inc. has reported several significant developments. Ascendiant Capital initiated coverage on Aclarion's stock, rating it a 'Buy' and setting a price target of $1.60, highlighting the potential benefits of Aclarion's proprietary NOCISCAN technology.
Aclarion also secured its 23rd U.S. patent from the United States Patent and Trademark Office. The patent pertains to advanced post-processing techniques designed to enhance the quality of spectral data from Magnetic Resonance Spectroscopy (MRS) exams, a key component of Aclarion's Nociscan solution.
In addition, Aclarion announced the release of its updated Nociscan 2.7 platform. The platform, which aids physicians in diagnosing and treating chronic low back pain, now includes user-friendly features and additional scalability and security measures, laying the groundwork for transitioning Nociscan from an augmented intelligence to a full artificial intelligence platform.
These are among the recent developments for Aclarion, Inc., which also includes its involvement in the LIFEHAB Trial where Nociscan is expected to play a key role. The company aims to establish Nociscan as a standard decision support tool in the diagnosis and treatment of chronic low back pain, a condition affecting an estimated 266 million people worldwide.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.